Xsolla Set to Launch the Xsolla StarNest Academy and Incubator Program in Baku
9.12.2024 10:00:00 CET | Business Wire | Press release
Collaboration in Azerbaijan Aims to Build a Thriving Game Development Ecosystem and Empower Local Talent with New Programs Launching in 2025
Xsolla, a global video game commerce company, has announced a strategic partnership with StarNest and Azerbaijan’s Innovation and Digital Development Agency (IDDA) to establish the Xsolla StarNest Academy and Incubator Program. This transformative collaboration was unveiled at the region's largest gaming festival, Gamesummit Winter Edition 2024, in Baku, Azerbaijan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209823866/en/
(Graphic: Xsolla)
Gamesummit Winter Edition 2024 spotlighted the growth of the gaming industry in Azerbaijan, featuring discussions on trends, global best practices, and presentations of locally developed games. At the festival, IDDA and Xsolla revealed plans to empower local developers, game designers, and studios with cutting-edge training, incubation and accelerator programs, and access to financial and technological resources. This partnership will redefine Azerbaijan's role in the global gaming industry while fostering local talent and innovation.
“This collaboration opens up extensive opportunities for implementing joint projects that will drive the development of Azerbaijan's gaming sector,” said Yevgeniya Bikmurzina, Head of IDDA's Innovation Ecosystem Department. “Azerbaijani game studios will have access to the tools and resources needed to make a mark in the global market.”
“This partnership represents a significant milestone for Xsolla as we collaborate with Azerbaijani leaders to unlock the region’s potential,” said Rytis Joseph Jan, SVP of Global Strategic Partnerships at Xsolla. “By combining our global expertise with the visionary leadership of our partners, we aim to empower the next generation of talent in Azerbaijan and drive meaningful innovation with global impact.”
Xsolla Incubator & Accelerator in Azerbaijan
The Xsolla Incubator and Accelerator will support Azerbaijan's game development community by providing tools, mentorship, and resources to turn ideas into successful projects. The Incubator will help early-stage developers refine concepts, gain technical expertise, and collaborate with international experts. The Accelerator will assist established studios in scaling their projects, offering access to funding, mentorship, and global industry connections. These programs aim to position Azerbaijan as a key player in the gaming industry, creating opportunities for local talent to succeed globally.
Xsolla StarNest Academy
The Xsolla StarNest Academy will provide 90 young individuals with specialized training in game development. Additionally, an incubation program will launch in 2025 to support local game studios, offering mentorship from international experts, access to financial resources, and opportunities to showcase games globally.
StarNest, an Azerbaijani telecommunications company, will lead efforts to secure a dedicated facility for the Academy, ensuring an environment conducive to growth and learning. IDDA will offer strategic oversight to align the initiative with Azerbaijan’s national goals for digital transformation.
Regional Headquarters
Xsolla is also exploring options to establish its regional headquarters for Central Asia in Baku to further support its commitment to the community and game developers in the region. Not only will it serve as a regional hub, but also a technology center for the leading edge development and support of its industry leading solutions.
With the Xsolla StarNest partnership this marks a new chapter for Azerbaijan’s gaming sector reflecting the shared vision to position the country as a regional game development and digital innovation leader.
This groundbreaking collaboration sets the stage for Azerbaijan to become a hub for gaming innovation and talent development. For more information, please visit: xsolla.blog/azerbaijan
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
About the Innovation and Digital Development Agency (IDDA)
IDDA is an Azerbaijani government agency specializing in digital diplomacy and analytics, offering research, training, and consultancy to enhance the digital presence of institutions. It plays a pivotal role in shaping modern diplomatic strategies through digital tools and data analysis.
For more information, visit idda.az
About StarNest
StarNest is a leading Azerbaijani telecommunications company providing internet and networking solutions, including broadband services, corporate connectivity, and IT infrastructure support. StarNest is dedicated to enabling technological growth and digital transformation across Azerbaijan.
For more information, visit starnest.io
About GameSummit
GameSummit is a prominent organization in Azerbaijan focused on the development of the gaming industry. Through events like Gamesummit Winter and Summer Editions, it creates opportunities for local game studios, promotes innovation, and raises awareness about career prospects in gaming and esports.
For more information, visit gamesummit.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209823866/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom